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Serum total immunoglobulin (G, A, M and E) and IgG subclass levels were studied in 23 patients with 
brittle asthma, 23 age- and sex-matched patients with mild asthma and 33 patients with recurrent 
infective exacerbations of their asthma. Patients with brittle asthma showed significantly reduced levels 
of IgG (mean f SD, 8.8 f 3.3 g l- ‘) compared to patients with mild asthma (11.0 f 2.5 g l- ‘) (PcO.008) 
with further significant reductions in the brittle compared to the mild group in IgG, (5.2 vs 6.3, 
P=O.O35), IgG, (2.4 vs 3.25, P<O.O06), IgG, (0.39 vs 0.55, PcO.05) and IgA (1.91 vs 2.38, PcO.03). There 
were no significant differences between the brittle group and the group with recurrent infective 
exacerbations for any parameter, but the latter group showed significantly reduced levels of IgG (8.2, 
P<O.OOl), IgG, (4.9, P~O.00001) and IgG, (2.5, WO.02) compared to the mild group. In all groups, 
there was no relationship between dose of inhaled steroids and levels of any antibody. These findings 
suggest that the presence of a mild degree of humoral immunodeficiency relates to severity of asthma, 
and suggests that immunoglobulin replacement therapy may be appropriate in patients with the more 
severe forms of asthma. 
RESPIR. MED. (1997) 91, 464-469 
Introduction 
Many patients with asthma report that upper respir- 
atory tract infections consistently cause an exacerba- 
tion of their condition, These infections are assumed 
to be viral in origin as bacterial infections are only 
rarely recorded as a cause of deterioration in asthma 
(1). Pan hypogammaglobulinaemia, either primary or 
acquired, is associated with recurrent persistent infec- 
tions of both the upper and lower respiratory tract 
(2,3). Less severe forms of antibody deficiency states 
such as IgA deficiency (4) and IgG subclass deficiency 
(5) have also been shown to be associated with 
recurrent respiratory tract infections. In a series of 58 
patients with chronic obstructive pulmonary disease 
(COPD) (6), one-quarter were shown to have an IgG 
subclass deficiency of some sort. IgG, levels were 
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positively correlated with FEV,, but this may have 
been an effect of steroid use. Total IgG levels in the 
COPD group were significantly lower than a group of 
normal controls. In a study of children with chronic 
sinusitis and ‘chronic bronchitis with a broncho- 
dilator response’ three-quarters were shown to have 
reduced levels of IgG, or IgG,, or both (7). In the 
same study, a significant proportion of a group of 
asthmatic children whose persistent symptoms were 
described as being unexplained by allergy had low 
IgG, and/or IgG, levels. A later study found five 
out of 75 children (44 with recurrent infective exacer- 
bations of asthma) had multiple IgG subclass defi- 
ciencies (8). Three subsequently improved with 
immunoglobulin replacement therapy. In a more 
recent study (9), 43% of a group of asthmatic patients 
who reported being infection prone were shown to 
have low IgG, levels. In these studies, the clinical and 
physiological features of the patients with asthma 
were poorly characterized. The aim of this study was 
to look for evidence of IgG subclass deficiencies 
in three groups of adult asthmatics: patients with 
brittle asthma; patients with recurrent infective 
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TABLE 1. Demographic details of the three groups of patients 
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Patients with 
Patients with infective Patients with 
brittle asthma exacerbations control asthma 
Number 
No. of females 
Age (years) 
Mean 
Range 
Smoking 
Current 
Ex-smoker 
Non-smoker 
Initial infective event 
FEV, 
Mean (SD) 
Range 
FEV, %PRED 
Mean (SD) 
Range 
Inhaled steroid dose &g) 
Group mean 
Range 
No. taking maintenance oral steroids 
Mean daily dose of those taking 
oral corticosteroids (mg) 
23 33 23 
15 (65%) 22 (67%) 15 (65%) 
42.4 51.0 43.2 
1463 17-70 17-63 
3 (13%) 2 (6.1%) 
5 (22%) 14 (42.4%) 
15 (65%) 17 (51.5%) 
10 (43.5%) 12/32 (37.5%) 
* 
* 
* 
* 
1474 
04000 
7 
12.0 
1 (4.4%) 
4 (17.4%) 
18 (78.2%) 
6122 (27.3%) 
2.03 (0.99) 2.64 (0.78) 
0.754992 1.54,45 
70.9% (23.6) 86.3 (18.5) 
233128% 522114% 
1264 796 
400-2400 094000 
2 0 
17.5 
*No data given - see text. 
tone patient unable to tolerate inhaled steroids due to ulcerative oral candidiasis. 
exacerbations of their asthma; and a control group of 
stable asthmatics without a history of upper respirat- 
ory tract infections consistently acting as triggers for 
their asthma. 
Patients and Methods 
Three groups of patients were studied. 
BRITTLE ASTHMA (M = 23) 
Brittle asthma was defined as persistent diurnal vari- 
ation in peak expiratory flow (PEF) of more than 
40% on most days, despite maximal medical therapy, 
usually comprising high-dose inhaled steroids and 
&agonists, in some cases comprising inhaled ipra- 
tropium bromide, oral theophyllines, oral & agonists 
and either maintenance or repeated courses of oral 
corticosteroids (10). Some of these patients had been 
successfully treated with continuous infusions of sub- 
cutaneous terbutaline (lo), but were still included in 
the study as their tendency to develop brittle asthma 
was still present if subcutaneous terbutaline was 
stopped. 
PATIENTS WITH RECURRENT EXACERBATIONS 
ASSOCIATED WITH A HISTORY OF A 
RESPIRATORY INFECTION (M = 33) 
This group of patients reported an exacerbation of 
asthma on every single occasion that they developed a 
symptomatic upper respiratory tract infection. 
CONTROL ASTHMATICS (M = 23) 
This group contained stable asthmatics, all taking 
inhaled steroids and &agonists, who reported that 
upper respiratory tract infections rarely, if ever, wors- 
ened their asthma. They were matched for age and 
sex with the patients in the group with brittle asthma. 
Blood was taken from each subject at a routine 
clinic visit for total IgG, IgM, IgA and IgE levels and 
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TABLE 2. Total immunoglobulin and IgG subclass levels in the three patient groups 
Patients with 
brittle asthma 
Patients with 
infective 
exacerbations 
Patients with 
mild asthma 
Number 23 33 23 
Mean (SD) Total *IgG (g 1 - ‘) 8.30 (3.3) 8.2 (1.8) 11.00 (25) 
I-Mean (SD) IgG, (g l- ‘) 5.2 (2.3) 4.90 (1.8) 6.31 (1.6) 
$Mean (SD) IgG, (g 1 - ‘) 2.4 (0.73) 2.5 1 (0.99) 3.25 (1.34) 
§Mean (SD) IgG, (g I- ‘) 0.39 (0.21) 0.50 (0.23) 0.55 (0.29) 
Mean (SD) IgG, (g 1 - ‘) 0.35 (0.33) 0.35 (0.3 1) 0.45 (0.37) 
Mean (SD) total IgA (g 1 - ‘) 1.9 1 (0.90) 2.12 (0.82) 2.38 (0.71) 
Mean (SD) total IgM (g 1 - ‘) 1.38 (0.63) 1.35 (0.81) 1.59 (0.60) 
Median total IgE (Ku 1 - ‘) 150 95 100 
Range of IgE (Ku 1 - ‘) ~25-1275 ~25-2515 ~25-1325 
*Group 1 vs Group 3 P<O.OOOl, Group 2 vs Group 3 P~O.00001. 
fGroup 1 vs Group 3 P=O*O35, Group 2 vs Group 3 PcO.002. 
fGroup 1 vs Group 3 P<O-006, Group 2 vs Group 3 PcO.02. 
§Group 1 vs Group 3 P<O-05. 
for IgG,, subclass levels. Antibody activity was 
determined in some of the patients in each group to 
pneumococcal capsular antigens (Pneumovax, SKF), 
tetanus and diphtheria toxoids, and to mixed 
Escherichia coli capsular polysaccharide antigens 
from six strains. On subsequent occasions, one 
patient in Group 1 and three in Group 2 were 
immunised to tetanus toxoid and one and two, 
respectively, to diphtheria toxoid. Blood was taken 
before and 2 weeks after immunisation for measure- 
ment of specific antibody levels. 
Serum immunoglobulin levels (IgG, IgA, IgM) 
were measured using a laser nephelometer (Behring) 
and known standards. The normal adult ranges for 
total IgG were 6-l 6 g 1 - ’ , for IgM 0.5-2.54 g l- ‘, for 
IgA 0.754.0 g 1 - ’ and for IgE O-200 Ku 1 - ‘. The 
normal ranges for the IgG subclasses (g l- ‘) were G, 
3.2-10.2, G, 1.2-6.6, G, 0.2-1.9 and G4 O-1.3. 
Statistical analysis employed Student’s t-test for un- 
paired samples, Fisher’s exact probability test for 2 x 2 
tables and the Wilcoxon Rank Sum test. Bartlett’s test 
for inhomogeneity of variance was used to determine 
normality of distribution and an analysis of variance 
applied to the data on inhaled steroid dose. 
Results 
Demographic details of the three groups of patients 
studied are shown in Table 1. Spirometric values are 
not recorded for the brittle group as, by definition, 
airflow measurements were widely variable. 
TOTAL IgG LEVELS (TABLE 2) 
Two patients in the brittle group had IgA deficiency 
(0.57 and 0.59 l- ‘); one also had low IgG, and IgG, 
levels, and the other had a slightly reduced IgG, level. 
Total IgG levels were reduced in two of 23 subjects in 
Group 1, four of 33 subjects in Group 2 but in no 
control subjects. The mean total IgG was significantly 
lower in the brittle group (8.8 g l- ‘) compared to the 
control group (11.0 g l- ‘) (P<O*OO8) and in the 
group with infective exacerbations (8.2 g 1 - ‘) com- 
pared to controls (P<O*OOOOl). Mean levels for IgA 
were significantly lower in the brittle group (1.91; SD 
O-91) compared to the control group (2.38; SD 0.71) 
(P~0.03) but there were no differences in the mean 
levels of IgM. 
IgG SUBCLASS LEVELS 
IgG, levels were reduced in five of 23 (22%) subjects 
with brittle asthma, six of 33 (18.2%) subjects with 
infective exacerbations of their asthma, but in none of 
the control asthmatics (Fig. 1). Mean group levels 
were significantly lower in both brittle (5.1 g 1 - ‘) and 
infective (4.9 g l- ‘) groups compared to controls 
(6.3 g l- ‘) (brittle vs control P=O*O35; infective vs 
controls P~O.002; Table 2). Two in each of Groups 1 
and 2 had slightly low IgG, levels ranging between 
0.95 and 1.1 g l- ‘. Mean levels for the brittle and 
infective groups were significantly less than controls 
(PcO.006 and ~0.002, respectively). Three patients 
with brittle asthma (13%) had low IgG, levels at O-07, 
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FIG. 1. Individual IgG, levels in the three patient 
groups. n , Patients taking maintenance oral pred- 
nisolone. Normal adult range (mean + 2 SD) indi- 
cated by horizontal lines. Group mean denoted by 
three parallel lines. 
1.5 
- 1 
. 
“L 
. 
0:. 
l se 
Brittle 
group 
Infective 
exacerbation 
group 
Control 
group 
FIG. 2. Individual IgG, levels in the three patient 
groups. W, Patients taking maintenance oral pred- 
nisolone. Normal adult range (mean + 2 SD) indi- 
cated by horizontal lines. Group mean + standard 
deviation denoted by three parallel lines. 
0.12 and 0.16 g l- ‘. One patient in Group 2 (3%) had 
a reduced level at 0.19 g 1 - ‘. Two control asthmatics 
(8.7%) had low IgG, levels at 0.12 and 0.19 g l- ‘. The 
mean IgG, was significantly reduced in the brittle 
group (0.39 g l- ‘) compared to controls (0.55 g l- ‘) 
(WO.05) (Table 2, Fig. 2). No patient in any group 
had a raised IgG, level. 
Three patients, one in each group, had a raised 
IgG, level at 1.5, 1.5 and 1.6 g l- ’ respectively. 
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FIG. 3. Individual IgE levels in the three patient 
groups. Lower limit of assay detection set at 25 Ku 
l- ‘. Bars are set at median values. 
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TABLE 3. Numbers of patients in the brittle (B) and 
infective (I) groups according to inhaled steroid dose 
Number in 
each group 
Dose Brittle Infective 
Subgroup 1 0-1OOOpg day-’ 11 14 
Subgroup 2 1050-15OOpg day-’ 5 11 
Subgroup 3 >15OO,ug day-’ 7 8 
Group mean values were similar. Overall, an IgG 
subclass deficiency of any sort was found in seven of 
23 (30%) subjects in Group 1, eight of 33 (24%) 
subjects in Group 2 and two of 23 (8.7%) subjects in 
Group 3 (P=O.O67 Fischer Exact test). 
Results were analysed by dose of inhaled steroid. In 
the brittle group and in the group with infective 
exacerbations of asthma, steroid dose was stratified 
into those taking up to 1000 pg day - ’ (Group 1) 
(mean inhaled steroid dose; brittle 900,ug day- ‘, 
infective 793 pug day- ‘), those taking between 1050 
and 1500 ,ug day - ’ (Group 2) (brittle 1500 pug day - ‘, 
infective 1418 pg day - ‘) and those taking more than 
15OOpg day- ’ (Group 3) (brittle 2071 ,ug day - I, 
infective 1875pg day ~ ‘) (Table 3). For the control 
group, inhaled steroid dose was regressed against the 
respective antibody levels. There was no relationship 
between inhaled steroid dose and levels of any anti- 
body for Groups 1 and 2 nor for the control patients 
(r values IgG - 0.22, IgG, - 0.13, IgG, - 0.08, IgG, 
- 0.19, IgG, 0, IgA - 0.10, IgM - 0.37). 
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TABLE 4. Distribution of IgG titres to tetanus, diphtheria, pneumococcal capsular antigen 
and Escherichia coli in the three patient groups 
Patients with 
brittle asthma 
Patients with 
infective 
exacerbations 
Patients with 
mild asthma 
n=lO n=9 II= 14 
>1:8 >1:32 >1:8 >1:32 >1:8 >132 
Tetanus 10 (100%) 4 40%) 8 (89%) 4 (45%) 10 (71%) 8 (57%) 
Diphtheria 9 (90%) 2 (20%) 5 (55%) 4 (45%) 8 (57%) 3 (21%) 
Pneumovax 5 (50%) 2 (20%) 6 (67%) 3 (33%) 12 (86%) 4 (29%) 
E. coli 10 (100%) 9 (90%) 9 (100%) 8 (89%) 14 (100%) 9 (65%) 
n = 10 for brittle group, n = 9 for infective group and n = 14 for controls. 
IgE LEVELS 
Total IgE levels ranged widely in all three groups with 
no significant differences between the groups (Table 2, 
Fig. 3). There was no significant difference in total 
IgE levels according to the presence or absence of 
IgG subclass deficiency. 
SPECIFIC ANTIBODY LEVELS 
These were measured in 10 patients in Group 1, nine 
patients in Group 2 and 14 patients in Group 3. There 
were no significant differences in the level of anti- 
bodies to tetanus, diphtheria, pneumococcal antigen 
and E. coli between the three groups (Table 4). 
Discussion 
This study concentrated on the immunoglobulin and 
antibody levels in two distinct clinical subgroups of 
asthma, namely brittle asthma and patients whose 
asthma always seemed to be exacerbated by minor 
upper respiratory tract infections. Significant reduc- 
tions in total IgG, IgG, and IgG, levels have been 
shown in both these groups compared to a control 
group of patients with milder asthma. This did not 
appear to be related to atopy, cigarette smoking or 
oral prednisolone dose. A reduction in IgA and in 
IgG, was also found in brittle asthma compared to 
the patients with milder asthma, all differences being 
independent of inhaled steroid dose. Relatively few 
patients had levels below the absolute normal range, 
and the changes are small compared to those seen in 
patients with the antibody deficiency syndrome, who 
have associated infective episodes (2,3). Being anti- 
bodies to protein antigens, anti-viral antibodies are 
largely generated from the IgG, or IgG, subclasses 
(11). Viral infections of the respiratory tract are 
known to increase bronchial hyper-reactivity (12) and 
to exacerbate asthma in both children (13) and in 
adults (14). Consequently, in patients with asthma 
who are more susceptible to viral infections, as may 
be the case with the degree of IgG,/IgGs deficiency 
described here, continuing persistent symptoms are 
likely to occur. 
Previous work in asthma has shown a reduction of 
IgG, levels in children (15). In adult asthmatics, IgG, 
and IgG, deficiency has been described (9), as has 
IgG, deficiency (16), but the present work is the first 
to characterize asthmatics into separate groups 
according to severity and to show lower levels of the 
IgG subclasses in the more severe groups. Brittle 
asthma is a severe condition with a high morbidity 
and a high mortality (17), and can be separated out 
on defined clinical criteria. Its separation as a distinct 
type of asthma is reinforced by the present finding of 
a relative immunodeficiency state. No relationship 
was found between IgG subclass deficiency and 
circulating IgE levels. 
Previous work on IgG subclass deficiency in asth- 
matic adults had not carefully characterized the 
patients from a clinical and physiological point of 
view (9,18), so the authors are unable to obtain 
information on whether those patients with IgG 
subclass deficiency were the more severe patients 
from previous published reports. The present findings 
do seem to correlate severity to humoral immune 
deficiency. Further studies are needed to assess 
whether in individuals with low IgG subclass levels, 
the values are consistently low or vary with time or 
with infective exacerbations. Studies on the therapeu- 
tic effect of replacement immunoglobulin are needed 
as the published literature to date involves very small 
numbers of rather poorly characterized asthmatic 
patients, although in some patients, a good response 
has been reported (8,19,20). Further studies are also 
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needed with respect to antibody responses to specific 
respiratory tract viruses such as influenza, respiratory 
syncytial virus and adenovirus. 
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